Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Karolinska Development AB (KDEV) NPV B

Sell:3.26 SEK Buy:3.37 SEK Change: 0.14 SEK (4.02%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:3.26 SEK
Buy:3.37 SEK
Change: 0.14 SEK (4.02%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:3.26 SEK
Buy:3.37 SEK
Change: 0.14 SEK (4.02%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Karolinska Development AB is a Sweden-based investment company. The Company provides capital to biotechnology firms, as well as develops and commercializes biotechnological products. Its activities are involved in a range of areas: oncology, infections and wound healing, women’s health, cardiovascular and hematology, medical equipment, diagnostics, pharmaceutical formulation, as well as implants, among others. The Company’s pharmaceuticals portfolio comprises: AXL1717 for non-small-cell lung carcinoma (NSCLC), APR-246 for ovarian cancer, Sevuparin for malaria, SHACT for pain relief at hysteroscopy and intrauterine device (IUD) insertion, and PC-mAB for acute coronary syndrome (ACS), among others. Furthermore, the Company controls a number of subsidiaries, such as Avaris AB, HBV Thernostica AB, KD Incentive AB, KDev Oncology AB and Limone AB.

Contact details

Address:
Tomtebodavagen 23 A
SOLNA
171 65
Sweden
Telephone:
+46 (8) 52486070
Website:
www.karolinskadevelopment.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
KDEV
ISIN:
SE0002190926
Market cap:
493.07 million SEK
Shares in issue:
64.17 million
Sector:
Pharmaceuticals
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Hans Wigzell
    Independent Chairman of the Board
  • Viktor Drvota
    Chief Executive Officer, Director
  • Tse Ping
    Independent Vice Chairman of the Board
  • Fredrik Jarrsten
    Chief Financial Officer
  • Elisabet Gimbringer
    Financial Manager
  • Eva Montgomerie
    Head of Accounting
  • Ulf Richenberg
    General Counsel
  • Esther Miralles Simo
    Analyst
  • Felicia Rittemar
    Analyst

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.